Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
The order this company entered each market — oldest to newest
Sign up to see the full signal feed
How Clarity Pharmaceuticals's international expansion compares to its competitors
Clarity PharmaceuticalsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Clarity PharmaceuticalsYou | 0 | 0 | 0% | 0 | 32 |
Head of Clinical Development
View postingSydney, New South Wales, Australia · 3w ago
Senior Manager, People & Culture
View postingUnited States · 4mo ago
Clinical Data Analyst and Statistical Programmer
View postingSydney, New South Wales, Australia · 4mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Clarity Pharmaceuticals' SECuRE trial for 67Cu-SAR-bisPSMA in prostate cancer completes dose escalation, shows promising efficacy and safety, and advances to Phase II expansion.
Clarity Pharmaceuticals starts Cohort Expansion Phase of SECuRE trial, treating first participant with 67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer.
Clarity Pharmaceuticals begins Phase III trial of 64Cu-SAR-bisPSMA for prostate cancer recurrence detection, aiming for FDA approval as a diagnostic agent.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Clarity Pharmaceuticals's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
